• Press Releases.png

    Press Releases

Global CRO Signs Seven-Year TrialOne® Agreement With OmniComm Systems

October 17, 2018

CONTACT :

Kuno van der Post
OmniComm Systems, Inc.
+1.954.473.1254
kvanderpost@omnicomm.com

New agreement expands commitment to TrialOne for early phase studies

Fort Lauderdale, FL - A global provider of drug development and commercialization solutions and services, has signed a new agreement extending its relationship with OmniComm Systems, Inc. (OTCQX: OMCM), a leading provider of clinical data management technology, for another seven years. Under the terms of the agreement, the CRO will use OmniComm’s TrialOne eClinical solution to automate early phase studies at one of its U.S.-based clinical research units.

The CRO selected TrialOne, apart from its status as the market-leading eSource and site automation system for Phase I clinics, because TrialOne enables research organizations to greatly improve the productivity and efficiency of their Phase I clinics.

TrialOne streamlines and automates key processes for early phase clinics, which drive efficiencies and reduce timelines and costs through faster and more directed volunteer recruitment, easy-to-build schedule-based workflows, real-time Bedside Data Collection (BDC), direct data capture from devices, sample processing automation and data processing. The automation reduces workload on clinic staff and improves the clinical trial experience for volunteers.

The browser-based, tablet-compatible system provides an advanced platform for automating clinic operations, complies with FDA 21 CFR Part 11, and supports data standards such as CDISC for faster and easier exporting and reporting of data.

“Each new contract documents TrialOne’s position as the market-leading eSource solution for Phase I clinics,” said Kuno van der Post, Ph.D., OmniComm’s chief commercial officer. “We’re excited to continue building our partnership with this leading CRO.”

About OmniComm Systems, Inc.
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world’s pharmaceutical, biotechnology, contract research organizations, diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies, research organizations drive efficiency in clinical development, better manage risks, ensure regulatory compliance and manage their clinical operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from more than 6,000 clinical trials. Please visit www.omnicomm.com for more information.

Trademarks
OmniComm, TrialMaster and TrialOne are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.

Topics: Corporate News